Antenatal magnesium sulphate reduces the risk of cerebral palsy in babies born< 30 weeks'
gestation. A guideline for its use in women at imminent risk of preterm birth was …

Objective The objective is to provide guidelines for the use of antenatal magnesium sulphate
for fetal neuroprotection of the preterm infant. Options Antenatal magnesium sulphate …

Background It is important to establish whether research recommendations regarding
magnesium sulphate for neuroprotection can be readily translated into clinical practice and …

Background Magnesium sulphate was introduced for fetal neuroprotection in Australia in
2010. The aim of this study was to determine how often antenatal magnesium sulphate is …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Background Australian and New Zealand clinical practice guidelines, endorsed by the
NHMRC in 2010, recommend administration of antenatal magnesium sulphate to women at …

Background Clinical practice guidelines recommend the use of antenatal magnesium
sulphate for fetal neuroprotection before preterm birth at< 30 weeks' gestation. Aims This …

Key content: The prevalence of preterm birth is increasing and owing to advances in
neonatal care, more infants are surviving. However, in parallel with this, the incidence of …

Background Magnesium sulphate is a common therapy in perinatal care. Its benefits when
given to women at risk of preterm birth for fetal neuroprotection (prevention of cerebral palsy …

The administration of magnesium sulphate to mothers at risk for preterm birth for fetal
neuroprotection has demonstrated to reduce the risk of cerebral palsy and gross motor …